A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer

NCT06331299 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

99

Enrollment

INDUSTRY

Sponsor class

Conditions

Bladder Cancer
Urothelial Carcinoma
Urothelial Carcinoma Bladder

Interventions

DRUG: UGN-103

Sponsor

UroGen Pharma Ltd.